
|Articles|July 26, 2002
Flexible light-based system gets FDA nod
TheraLight received clearance from the U.S. Food and Drug Administrationto market its UV120-2 UVA/UUVB Phototherapy System for the treatment ofpsoriasis, vitiligo, atopic dermatitis and seborrheic dermatitis.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
JAK Inhibitors Show Comparable Safety to TNF Antagonists
2
First-in-Class Topical GT20029 Demonstrates Promising Phase 2 Efficacy and Tolerability for AGA
3
Medicus Pharma Completes Phase 2 Enrollment of D-MNA Study to Non-Invasively Treat BCC
4
Balancing Pathophysiology and Patient Lifestyle in Acne Management: Part 1
5


















